Interim FDG-PET/CT for Response Assessment of Lymphoma

被引：12

作者：

Zeman, Merissa N. ^{[1
]}

Akin, Esma A. ^{[2
,3
]}

Merryman, Reid W. ^{[4
]}

Jacene, Heather A. ^{[1
,5
,6
]}

机构：

[1] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02215 USA

[2] Harvard Med Sch, Boston, MA USA

[3] George Washington Univ, Med Fac Associates, Dept Radiol, Div Nucl Med, Washington, DC USA

[4] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA USA

[5] Dana Farber Canc Inst, Dept Imaging, Boston, MA USA

[6] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiol, 450 Brookline Ave, Boston, MA 02215 USA

来源：

SEMINARS IN NUCLEAR MEDICINE | 2023年 / 53卷 / 03期

关键词：

POSITRON-EMISSION-TOMOGRAPHY; B-CELL LYMPHOMA; PROGRESSION-FREE SURVIVAL; ADVANCED HODGKIN LYMPHOMA; THERAPY F-18-FDG PET/CT; DETUDES DES LYMPHOMES; RISK-ADAPTED THERAPY; PROGNOSTIC VALUE; OPEN-LABEL; STAGE-III;

D O I：

10.1053/j.semnuclmed.2022.10.004

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The clinical use and prognostic value of interim FDG-PET/CT (iPET/CT), which is performed after treatment initiation but prior to its completion, varies by lymphoma subtype. Evidence supporting the prognostic value of iPET/CT is more robust for classical Hodgkin lymphoma (cHL), and in this lymphoma subtype, response-adapted treatment approaches guided by iPET/CT are a widely used standard of care for first-line therapy. The data supporting use of iPET/CT among patients with non-Hodgkin lymphoma (NHL) is less well-established, but failure to achieve complete metabolic response on iPET/CT is generally considered a poor prognostic factor with likely consequences for progression free survival. This review will present the available evidence supporting use of iPET/CT in lymphoma patients, particularly as it relates to prognostication and the ability to inform response-adapted treatment strate-gies. The latter will be addressed through a discussion on the major iPET-response adapted clinical trials with mention of ongoing trials. Special attention will be given to cHL and a few subtypes of NHL, including diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and peripheral T cell lymphoma (PTCL). Semin Nucl Med 53:371-388 (c) 2022 Elsevier Inc. All rights reserved.

引用

页码：371 / 388

页数：18

共 88 条

[21] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].

Cheson, Bruce D. ;

Fisher, Richard I. ;

Barrington, Sally F. ;

Cavalli, Franco ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Lister, T. Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+

[22] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte [J].

Coiffier, Bertrand ;

Thieblemont, Catherine ;

Van Den Neste, Eric ;

Lepeu, Gerard ;

Plantier, Isabelle ;

Castaigne, Sylvie ;

Lefort, Sophie ;

Marit, Gerald ;

Macro, Margaret ;

Sebban, Catherine ;

Belhadj, Karim ;

Bordessoule, Dominique ;

Ferme, Christophe ;

Tilly, Herve .

BLOOD, 2010, 116 (12) :2040-2045

[23] Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma [J].

Connors, J. M. ;

Jurczak, W. ;

Straus, D. J. ;

Ansell, S. M. ;

Kim, W. S. ;

Gallamini, A. ;

Younes, A. ;

Alekseev, S. ;

Illes, A. ;

Picardi, M. ;

Lech-Maranda, E. ;

Oki, Y. ;

Feldman, T. ;

Smolewski, P. ;

Savage, K. J. ;

Bartlett, N. L. ;

Walewski, J. ;

Chen, R. ;

Ramchandren, R. ;

Zinzani, P. L. ;

Cunningham, D. ;

Rosta, A. ;

Josephson, N. C. ;

Song, E. ;

Sachs, J. ;

Liu, R. ;

Jolin, H. A. ;

Huebner, D. ;

Radford, J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (04) :331-344

[24] Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients [J].

Cottereau, Anne-Segolene ;

El-Galaly, Tarec Christoffer ;

Becker, Stephanie ;

Broussais, Florence ;

Petersen, Lars Jelstrup ;

Bonnet, Christophe ;

Prior, John O. ;

Tilly, Herve ;

Hutchings, Martin ;

Casasnovas, Olivier ;

Meignan, Michel .

JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (04) :589-595

[25] PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts [J].

Desai, Sanjal H. ;

Pederson, Levi D. ;

Laplant, Betsy ;

Mwangi, Raphael ;

Maurer, Matthew J. ;

Young, Jason R. ;

Macon, William R. ;

King, Rebecca L. ;

Wang, Yucai ;

Cerhan, James R. ;

Feldman, Andrew L. ;

Inwards, David J. ;

Micallef, Ivana N. ;

Johnston, Patrick B. ;

Porrata, Luis F. ;

Ansell, Stephen M. ;

Habermann, Thomas M. ;

Witzig, Thomas E. ;

Nowakowski, Grzegorz S. .

BLOOD CANCER JOURNAL, 2022, 12 (05)

[26] Circulating Tumor DNA Integrated with Interim [18F]FDG PET Is Highly Effective in Predicting Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma Treated with the Begev Regimen [J].

Di Trani, Martina ;

Ricci, Francesca ;

Sollini, Martina ;

Calabretta, Eleonora ;

Cristaldi, Vanessa ;

Bonovas, Stefanos ;

Marino, Fabrizio ;

Mazza, Rita ;

Bruscaggin, Alessio ;

Pirosa, Maria Cristina ;

Chiti, Arturo ;

Rossi, Davide ;

Santoro, Armando ;

Carlo-Stella, Carmelo .

BLOOD, 2021, 138

[27] Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial [J].

Duehrsen, Ulrich ;

Mueller, Stefan ;

Hertenstein, Bernd ;

Thomssen, Henrike ;

Kotzerke, Joerg ;

Mesters, Rolf ;

Berdel, Wolfgang E. ;

Franzius, Christiane ;

Kroschinsky, Frank ;

Weckesser, Matthias ;

Kofahl-Krause, Dorothea ;

Bengel, Frank M. ;

Duerig, Jan ;

Matschke, Johannes ;

Schmitz, Christine ;

Poeppel, Thorsten ;

Ose, Claudia ;

Brinkmann, Marcus ;

La Rosee, Paul ;

Freesmeyer, Martin ;

Hertel, Andreas ;

Hoeffkes, Heinz-Gert ;

Behringer, Dirk ;

Prange-Krex, Gabriele ;

Wilop, Stefan ;

Krohn, Thomas ;

Holzinger, Jens ;

Griesshammer, Martin ;

Giagounidis, Aristoteles ;

Raghavachar, Aruna ;

Maschmeyer, Georg ;

Brink, Ingo ;

Bernhard, Helga ;

Haberkorn, Uwe ;

Gaska, Tobias ;

Kurch, Lars ;

van Assema, Danielle M. E. ;

Klapper, Wolfram ;

Hoelzer, Dieter ;

Geworski, Lilli ;

Joeckel, Karl-Heinz ;

Scherag, Andre ;

Bockisch, Andreas ;

Rekowski, Jan ;

Huettmann, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (20) :2024-+

[28] Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High-Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS [J].

Dupuis, Jehan ;

Berriolo-Riedinger, Alina ;

Julian, Anne ;

Brice, Pauline ;

Tychyj-Pinel, Christelle ;

Tilly, Herve ;

Mounier, Nicolas ;

Gallamini, Andrea ;

Feugier, Pierre ;

Soubeyran, Pierre ;

Colombat, Philippe ;

Laurent, Guy ;

Berenger, Nathalie ;

Casasnovas, Rene-Olivier ;

Vera, Pierre ;

Paone, Gaetano ;

Xerri, Luc ;

Salles, Gilles ;

Haioun, Corinne ;

Meignan, Michel .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (35) :4317-4322

[29] Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements [J].

Eertink, J. J. ;

Arens, A. I. J. ;

Huijbregts, J. E. ;

Celik, F. ;

de Keizer, B. ;

Stroobants, S. ;

de Jong, D. ;

Wiegers, S. E. ;

Zwezerijnen, G. J. C. ;

Burggraaff, C. N. ;

Boellaard, R. ;

de Vet, H. C. W. ;

Hoekstra, O. S. ;

Lugtenburg, P. J. ;

Chamuleau, M. E. D. ;

Zijlstra, J. M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (03) :943-952

[30] Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients [J].

Eertink, J. J. ;

Burggraaff, C. N. ;

Heymans, M. W. ;

Duehrsen, U. ;

Huettmann, A. ;

Schmitz, C. ;

Mueller, S. ;

Lugtenburg, P. J. ;

Barrington, S. F. ;

Mikhaeel, N. G. ;

Carr, R. ;

Czibor, S. ;

Gyoerke, T. ;

Ceriani, L. ;

Zucca, E. ;

Hutchings, M. ;

Kostakoglu, L. ;

Loft, A. ;

Fanti, S. ;

Wiegers, S. E. ;

Pieplenbosch, S. ;

Boellaard, R. ;

Hoekstra, O. S. ;

Zijlstra, J. M. ;

de Vet, H. C. W. .

BLOOD ADVANCES, 2021, 5 (09) :2375-2384

← 1 2 3 4 5 6 7 8 9 →